Stay Curious. Stay Connected.
MailNewsletters♡Donate Now
Sign up
*Password must be at least 8 characters and contain one uppercase letter, one lowercase letter, one number and one symbol.
Already have an account?
By submitting, you consent that you are at least 18 years of age and to receive information about MPR's or APMG entities' programs and offerings. The personally identifying information you provide will not be sold, shared, or used for purposes other than to communicate with you about MPR, APMG entities, and its sponsors. You may opt-out at any time clicking the unsubscribe link at the bottom of any email communication. View our Privacy Policy.
Sign in to your profile
Forgot Password?
New to MPR News?
Welcome back
to news
for you
Reset Password

Enter the username on file and we'll send you a code to reset your password.

Still require assistance or not sure what your User Name is?
Welcome back
to news
for you
Email Verification

A verification code has been emailed to

Still awaiting the code?
Morning Edition
Cathy Wurzer

What comes next for Mayo’s COVID-19 plasma program?

Go Deeper.

Create an account or log in to save stories.

Like this?

Thanks for liking this story! We have added it to a list of your favorite stories.

The New York Times is reporting this week that a group of top federal health officials have privately voiced concern about a prominent COVID-19 research program run by the Mayo Clinic. The program is testing the use of blood plasma from recovered patients to treat those who are seriously ill with the virus.

Mayo Clinic recently reported promising results, and enrollment in the program has surged. But according to the Times, Dr. Anthony Fauci and other top health officials stepped in last week to block what's known as an “emergency use authorization” for the plasma treatment.

For more, MPR News host Cathy Wurzer talked with Dr. Scott Wright, who is helping oversee the Mayo Clinic’s convalescent plasma program.